BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 26, 2013
View Archived Issues
BMS-986015 shows efficacy in a novel animal model of lymphoma
Read More
Recommended phase II dose for Genopep-1 determined
Read More
Alchemia signs multitarget drug discovery collaboration with AstraZeneca
Read More
Nutrition Science Partners commences first trial in phase III ulcerative colitis program
Read More
CCG-203971 inhibits Rho-regulated transcription in metastatic melanoma cell lines
Read More
Kyowa Hakko Kirin reviews highlights of first quarter 2013
Read More
First clinical results of CNV-2197944 presented
Read More
arGEN-X progresses ARGX-113 into preclinical development for autoimmune disorders
Read More
Dose-finding phase II study of ARX-04 Sufentanil NanoTab achieves primary endpoint
Read More
MBio Diagnostics completes phase I of tuberculosis serology program
Read More
New TNF-like ligand 1a-binding antibodies designed at Cephalon
Read More
Mochida files for Japanese approval of treprostinil
Read More
Summit reports encouraging results from phase I trial of novel antibiotic
Read More
Dosing begins in phase I study of antibody for treatment of AL amyloidosis
Read More
Lambrolizumab designated as breakthrough therapy by the FDA
Read More
Immunomic Therapeutics reports results from study of Japanese red cedar allergy vaccine
Read More
XBiotech begins enrollment in phase III trial of True Human anticancer antibody
Read More
Achaogen to receive additional funding from BARDA for phase III study of plazomicin
Read More
BioMarin files MAA with EMA for enzyme replacement therapy Vimizim
Read More
Bronchitol phase III trial does not meet primary endpoint
Read More
Aubagio delays onset of clinically definite MS in TOPIC study
Read More
Treatment with novel D1 receptor agonist leads to cognitive enhancement in patients with SPD
Read More
AZD-8186 described as a potent and selective PI3Kbeta inhibitor
Read More
Spanish researchers disclose novel compounds with antileishmanial activity
Read More
New start-up company focused on rare diseases is created
Read More
Novartis presents new isocitrate dehydrogenase inhibitors
Read More
Taiwanese scientists divulge novel cannabinoid CB1 receptor antagonists
Read More